


Journal Pre-proof

Low gestational vitamin D level and childhood asthma are related to impaired lung function in high-risk children

Hanna M. Knihtilä, MD, PhD, Benjamin J. Stubbs, BA, Vincent J. Carey, PhD, Nancy Laranjo, BA, Su H. Chu, PhD, Rachel S. Kelly, PhD, Robert S. Zeiger, MD, PhD, Leonard B. Bacharier, MD, George T. O'Connor, MD, MS, Jessica Lasky-Su, ScD, Scott T. Weiss, MD, MS, Augusto A. Litonjua, MD, MPH



PII: S0091-6749(21)00085-3

DOI: <https://doi.org/10.1016/j.jaci.2020.12.647>

Reference: YMAI 14934

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 28 June 2020

Revised Date: 1 December 2020

Accepted Date: 31 December 2020

Please cite this article as: Knihtilä HM, Stubbs BJ, Carey VJ, Laranjo N, Chu SH, Kelly RS, Zeiger RS, Bacharier LB, O'Connor GT, Lasky-Su J, Weiss ST, Litonjua AA, Low gestational vitamin D level and childhood asthma are related to impaired lung function in high-risk children, *Journal of Allergy and Clinical Immunology* (2021), doi: <https://doi.org/10.1016/j.jaci.2020.12.647>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.



Low gestational vitamin D level and childhood asthma are related to impaired lung function in high-risk children

VDAART cohort:

Pregnant women at high risk of offspring asthma



570 mother-child pairs with data available



Risk factors:




Decreasing mean vitamin D level quartile at 10-18 and at 32-38 gestational weeks



Child asthma

Lung function at age 4-6 years:

Decreased FEV_1 (β -0.018 L)*
Increased R5 (β 0.021 kPa/L/s)*



Decreased FEV_1 (β -0.099 L)*
Increased R5 (β 0.065 kPa/L/s)*

Abbreviations: FEV_1 , forced expiratory volume in one second; R5, respiratory resistance at 5 Hz; VDAART, Vitamin D Antenatal Asthma Reduction Trial. * $P < 0.01$.

Low gestational vitamin D level and childhood asthma are related to impaired lung function in high-risk children

Authors: Hanna M. Knihtilä, MD, PhD¹; Benjamin J. Stubbs, BA¹; Vincent J. Carey, PhD¹; Nancy Laranjo, BA¹; Su H. Chu, PhD¹; Rachel S. Kelly, PhD¹; Robert S. Zeiger, MD, PhD²; Leonard B. Bacharier, MD³; George T. O'Connor, MD, MS⁴; Jessica Lasky-Su, ScD¹; Scott T. Weiss, MD, MS^{1*}; Augusto A. Litonjua, MD, MPH^{5*}

Affiliations: ¹Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States

²Departments of Allergy and Research and Evaluation, Kaiser Permanente Southern California Region, San Diego, CA and Pasadena, CA

³The Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis

⁴The Pulmonary Center, Department of Medicine, Boston University School of Medicine

⁵Division of Pediatric Pulmonary Medicine, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, NY, United States

*These authors contributed equally

Corresponding author: Scott T. Weiss, MD, MS. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA 02115. Telephone: 617-525-2278. Fax: 617-525-0958. Email: scott.weiss@channing.harvard.edu.

24 **Funding:** National Heart Lung and Blood Institute R01HL091528 and UH3OD023268. HMK is
25 supported by Jane and Aatos Erkkö Foundation, Paulo Foundation, and the Pediatric Research
26 Foundation.

27
28 **Conflict of interest disclosures:** AAL reports personal fees from UpToDate, Inc., outside the
29 submitted work. STW reports other from UpToDate, outside the submitted work. GTO reports
30 grants from NIH, during the conduct of the study. LBB reports grants from NIH/NHLBI, during the
31 conduct of the study; personal fees from GlaxoSmithKline, personal fees from Genentech/Novartis,
32 personal fees and non-financial support from Merck, personal fees from DBV Technologies,
33 personal fees and non-financial support from Teva, personal fees and non-financial support from
34 Boehringer Ingelheim, personal fees from AstraZeneca, personal fees from WebMD/Medscape,
35 personal fees from Sanofi/Regeneron, personal fees from Vectura, personal fees from Circassia,
36 outside the submitted work. RSZ reports grants from NHLBI, during the conduct of the study;
37 grants from Aerocrine, grants from Genentech, grants from MedImmune/AstraZeneca, grants from
38 Merck, personal fees from AstraZeneca, personal fees from Genentech, personal fees from
39 Novartis, personal fees from TEVA, personal fees from GlaxoSmithKline, personal fees from
40 Regeneron Pharmaceuticals, grants from GlaxoSmithKline, grants from ALK Pharma, grants from
41 TEVA, outside the submitted work. NL reports grants from NIH, during the conduct of the study.
42 The remaining authors declare that they have no relevant conflicts of interest.

43
44 **Word count:** 3703

ABSTRACT

Background: Lung function impairment in early life often persists into adulthood. Therefore, identifying risk factors for low childhood lung function is crucial.

Objective: We examined the effect of 25-hydroxyvitamin D (25[OH]D) level and childhood asthma phenotype on childhood lung function in the Vitamin D Antenatal Asthma Reduction Trial (VDAART).

Methods: 25(OH)D level was measured at set time points in mothers during pregnancy and in children during early life. Based on parental reports, children were categorized into three clinical phenotypes: asymptomatic/infrequent wheeze, early transient wheeze, and asthma at age 6 years. Lung function was assessed with impulse oscillometry at ages 4, 5, and 6 years and with spirometry at ages 5 and 6 years.

Results: 570 mother-child pairs were included in this post-hoc analysis. Mean gestational 25(OH)D level quartiles were negatively associated with child respiratory resistance at 5 Hz (R5) from age 4 to 6 years (β -0.021 kPa/L/s; 95% CI -0.035 to -0.007; $P=0.003$) and positively associated with FEV₁ (β 0.018 L; 95% CI 0.005 to 0.031; $P=0.008$) and FVC (β 0.022 L; 95% CI 0.009 to 0.036; $P=0.002$) from age 5 to 6 years. Children with asthma at age 6 years had lower lung function from age 4 to 6 years than the asymptomatic/infrequent wheeze group (β 0.065 kPa/L/s; 95% CI 0.028 to 0.102; $P<0.001$ for R5 and β -0.063 L; 95% CI -0.099 to -0.028; $P<0.001$ for FEV₁).

Conclusion: Low gestational 25(OH)D level and childhood asthma are important risk factors for decreased lung function in early childhood.

Clinicaltrials.gov identifier: NCT00920621

Abstract word count: 249

Clinical implication: Low gestational vitamin D level appears as an important modifiable risk factor for impaired lung function in early childhood.

Capsule summary: This study provides evidence that low gestational vitamin D level and childhood asthma phenotype are important and independent risk factors for decreased childhood lung function from 4 to 6 years of age.

Key words: Vitamin D; Childhood asthma; Lung function; Spirometry; Impulse oscillometry; VDAART; Tobacco smoke

Abbreviations:

25(OH)D	25-hydroxyvitamin D
CI	Confidence interval
COPSAC ₂₀₁₀	Copenhagen Prospective Studies on Asthma in Childhood 2010
FEV ₁	Forced expiratory volume in 1 second
FVC	Forced vital capacity
IOS	Impulse oscillometry
R5	Respiratory resistance at 5 Hz
R5-20	Difference between respiratory resistance at 5 and 20 Hz
VDAART	Vitamin D Antenatal Asthma Reduction Trial

INTRODUCTION

Subjects with childhood asthma often present with lower levels of lung function than their healthy peers. By school age, impairment of lung function is already detectable in a substantial proportion of asthmatics and often persists into adulthood.^{1,2} Furthermore, unselected birth cohorts have demonstrated that in some cases, impairment of lung function may already be detectable in early infancy.^{3,4} These findings suggest that the origins of lung function impairment may be related to environmental or genetic factors influencing fetal lung development. Therefore, identifying and minimizing risk factors for reduced growth in early life lung function is crucial for later respiratory health.

Vitamin D deficiency (25-hydroxyvitamin D (25[OH]D) level of <20 ng/ml) and insufficiency (25[OH]D level of 20 to <30 ng/ml) are extremely common worldwide, especially in pregnant and lactating women.^{5,6} Vitamin D has been linked to fetal lung and immune system development⁷. Furthermore, animal studies have demonstrated clear structural and functional lung changes in the offspring of vitamin D-deficient mothers,^{8,9} and clinical trials have suggested that high-dose prenatal vitamin D₃ supplementation may decrease early life wheezing.^{10,11} However, studies on the association between gestational vitamin D and offspring lung function in humans have yielded conflicting results.¹²⁻¹⁵ We conducted the Vitamin D Antenatal Asthma Reduction Trial (VDAART) to examine the potential of high-dose prenatal vitamin D₃ supplementation for preventing offspring asthma and wheeze. Follow-up data from the VDAART suggested that although the supplementation did not reduce the 6-year incidence of childhood asthma and recurrent wheeze, it may have some influence on childhood lung function.¹⁶ However, the Copenhagen Prospective Studies on Asthma in Childhood 2010 (COPSAC₂₀₁₀) trial observed no associations between high-dose prenatal vitamin D₃ supplementation and lung function at age 6 years.¹⁷

115

116 In the present post-hoc study, we investigated the association of 1) 25(OH)D levels during
117 pregnancy and early life, and 2) childhood asthma phenotype with lung function in early childhood
118 obtained via impulse oscillometry (IOS) and spirometry in the VDAART cohort.

METHODS

Study populations

The VDAART (clinicaltrials.gov identifier: NCT00920621) is a double-blinded randomized controlled trial that randomized pregnant women at 10-18 gestational weeks to receive either high-dose vitamin D₃ supplementation (4000 IU/d) or placebo in addition to regular prenatal vitamin D₃ supplementation (400 IU/d).¹⁰ The women and/or the biological fathers of the children had a history of asthma, eczema, or allergic rhinitis. At enrollment, the women filled out a questionnaire¹⁰ which included information on their demographic characteristics, medical history, active tobacco smoking, and tobacco smoking in the household. Only women who were nonsmokers were included in the trial. Subjects from both the intervention and placebo groups were included in the present post-hoc analysis.

Asthma phenotypes

The health, respiratory symptoms, and medication use of the children was monitored by telephone every 3 months and in-person annually from birth to age 6 years, and used to categorize the children into three clinical phenotypes: 1) asthma at age 6 years was defined as physician-diagnosed asthma at any time from birth to age 6 years and a report of asthma medication use or wheeze after 5 years of age,¹⁶ 2) early transient wheeze was defined as physician-diagnosed asthma or recurrent wheeze (≥ 2 episodes based on predefined criteria) at any time from birth to age 3 years¹⁰ but no asthma at age 6 years, 3) subjects who did not meet the criteria of early transient wheeze or asthma at age 6 years were categorized as asymptomatic/infrequent wheeze.

25-hydroxyvitamin D measurements

Plasma 25(OH)D level was measured in the mothers at baseline (10-18 gestational weeks) and at third trimester (32-38 gestational weeks) and in the children at age 1 and 3 years using the DiaSorin

Liaison chemiluminescence immunoassay. Chromatography-tandem mass spectrometry (LC-MS/MS) was used to determine 25(OH)D level from cord blood drawn at the time of delivery.¹⁸

Lung function measurements

Methods for quality control of the lung function measurements have been previously published.¹⁶ IOS measurements were performed at ages 4, 5, and 6 years using the Jaeger MasterScreen IOS System (VyaireTM Medical, Inc.). The method uses pulse signals of different frequencies that are superimposed on tidal breathing to determine different measures of lung mechanics, such as respiratory resistance at 5 Hz (R5) which is considered to reflect the resistance of the whole respiratory tract and the difference between respiratory resistance at 5 and 20 Hz (R5-20) which is thought to reflect mainly peripheral airway properties.^{19,20} IOS was performed with the child sitting and using a nose clip. In total, 4-10 trials were recorded and the measurement was regarded as successful if at least 2 acceptable and repeatable recordings with a regular tidal breathing pattern of at least 20 seconds were acquired. The mean value for each IOS index was calculated from the acceptable IOS recordings and used in the analyses.

Spirometry measurements were performed at ages 5 and 6 years according to the American Thoracic Society and European Respiratory Society guidelines²¹ using the Jaeger MasterScreen PFT System (VyaireTM Medical, Inc.). The measurements were performed with the child standing and using a nose clip. In total, 4-10 trials were recorded and the measurement was regarded as successful if at least 2 acceptable and repeatable recordings were acquired. The mean value for each spirometry index was calculated from the acceptable spirometry recordings and used in the analyses.

168 Parents were instructed to cease their child's bronchodilator medications at least 8 hours before and
169 inhaled corticosteroids or leukotriene modifiers at least 24 hours before the lung function
170 measurements.

171

172 **Statistical analyses**

173 Student T test and chi-squared tests were used to compare demographic data between groups. Due
174 to the lack of validated multiethnic reference values for IOS, the lung function data were analyzed
175 using height, sex, and race adjusted models. Differences in the longitudinal lung function
176 trajectories between groups were evaluated using linear mixed effects models. Time-dependent
177 covariates included in the models were child height and child age, and fixed covariates were child
178 sex, child race, and study site. To evaluate the association between plasma 25(OH)D level and lung
179 function, children were grouped into quartiles based on the 25(OH)D measurement of interest, and
180 the trend between these 25(OH)D level quartiles (ordinal variable) was evaluated in the linear
181 mixed effects models. R Version 3.6.0 was used for the statistical analyses and a confidence level
182 of 95% was applied.

RESULTS

Baseline characteristics

A flow chart of the study is presented in **Figure 1**. In total, 570 (71%) of the 806 children in the VDAART cohort performed at least 1 successful lung function measurement, providing data on a total of 1036 IOS measurements and 615 spirometry measurements that were used in the analyses. Of the 570 children, 569 (99.8%) had data on maternal 25(OH)D level from at least one time-point available and 564 (98.9%) had data on their childhood asthma phenotype. **Figure E1** presents the upset diagrams for the repeated lung function measurements. 357 (66%) of the 543 children with data on IOS performed successful measurements on at least 2 separate visits and 175 (40%) of the 438 children with data on spirometry performed successful measurements on both of the 2 visits. **Table 1** presents the baseline characteristics of the study subjects and those excluded due to missing data or unsuccessful lung function measurements. No differences between these groups were observed except for maternal hay fever (66% for the study subjects vs. 59% for the excluded subjects; $P=0.042$) and study site distribution (study subjects vs. excluded subjects: 28% vs. 35% for Boston, 33% vs. 37% for San Diego, and 40% vs. 28% for St. Louis; $P=0.047$).

25-hydroxyvitamin D and lung function

Mean gestational 25(OH)D level quartiles showed a positive trend with offspring lung function at ages 4, 5, and 6 years (**Figure 2**). In the linear mixed effects models, baseline, third trimester, and mean gestational 25(OH)D level quartiles showed significant negative associations with the longitudinal trajectories of child R5 and R5-20 and positive associations with forced expiratory volume in 1 second (FEV_1) and forced vital capacity (FVC), all indicating an increasing level of lung function with increasing 25(OH)D level quartile (**Table 2**). At the age of 6 years, offspring of mothers in the highest mean gestational 25(OH)D level quartile had 12 mL higher FEV_1 (10.7%, 1.24 L vs. 1.12 L) and 0.08 kPa/L/s lower R5 (8.7%, 0.84 kPa/L/s vs. 0.92 kPa/L/s) levels than

those with mothers in the lowest quartile. However, no associations between maternal 25(OH)D level quartiles and child FEV₁/FVC ratio was observed. All associations between maternal 25(OH)D level quartiles and child lung function remained significant after adjusting for maternal age, education, asthma, and household tobacco smoking at enrollment, except for the association between baseline 25(OH)D level and R5-20 (**Table E1**). Similarly, all associations remained significant after adjusting for allergic sensitization, except for the associations of baseline 25(OH)D level quartiles with R5-20 and FEV₁ (**Table E2**). No consistent differences in the association between gestational 25(OH)D level quartiles and child lung function were observed when stratified by child sex or race (**Table E3** and **Table E4**). Child 25(OH)D level quartiles at birth, age 1 year, and age 3 years did not show significant associations with lung function except for cord blood 25(OH)D level quartiles which were negatively associated with R5 and R5-20 (**Table E5**).

We performed a separate analysis to compare the lung function of children whose mothers had either deficient (<20 ng/ml, n=91), insufficient (20-29 ng/ml, n=61), or sufficient (≥30 ng/ml, n=96) 25(OH)D level at both baseline and third trimester. Similar to the 25(OH)D level quartiles, these gestational 25(OH)D level groups showed a positive trend with offspring lung function from 4 to 6 years of age (**Figure 4**). In the linear mixed effects models, the gestational 25(OH)D level groups showed significant positive associations with the longitudinal trajectories of child R5 and R5-20, and negative associations with FEV₁ and FVC (**Table E6**).

Childhood asthma phenotype and lung function

Children with asthma at age 6 years had lower levels of lung function from 4 to 6 years of age than the asymptomatic/infrequent wheeze group and differences between the lung function of the transient early wheeze group and the asymptomatic/infrequent wheeze group were consistently smaller than what was seen between the asthma group and the asymptomatic/infrequent wheeze

group (**Figure 4**). In the mixed effects models, all IOS and spirometry indices demonstrated significantly lower longitudinal lung function levels in children with asthma at age 6 years than in the asymptomatic/infrequent wheeze group, whereas the early transient wheeze group only differed from the asymptomatic/infrequent wheeze group in relation to R5-20 (**Table 3**). All associations between the asthma phenotypes and lung function remained significant after adjusting for allergic sensitization (**Table E7**). No significant interactions between child asthma status at age 6 years and gestational 25(OH)D level quartiles were observed for the longitudinal lung function trajectories (**Table E8**).

Multivariable model of different risk factors for decreased lung function

Multivariable models evaluating the effects of mean gestational 25(OH)D level quartiles, childhood asthma phenotype, preterm birth, and household tobacco smoking during pregnancy on childhood longitudinal lung function trajectories are presented in **Table 4**. In these models, mean gestational 25(OH)D quartiles showed significant negative associations with child R5 and R5-20 and positive associations with FEV₁ and FVC. Asthma at age 6 years was associated with increased R5 and R5-20 and decreased FEV₁ and FEV₁/FVC and a borderline significant decrease in FVC, whereas the early transient wheeze phenotype only showed increased FVC when compared to the asymptomatic/infrequent wheeze group. Household tobacco smoking at study enrollment was associated with increased R5 and R5-20, but not with significant changes in the spirometry indices. Preterm birth was associated with increased R5-20 and decreased FEV₁, as well as borderline significant changes in R5 and FVC.

DISCUSSION

The present study provides evidence that low gestational 25(OH)D level and childhood asthma phenotype are important and independent risk factors for decreased lung function from age 4 to 6 years. Gestational 25(OH)D level at baseline (10-18 gestational weeks) and third trimester (32-38 gestational weeks) were both significantly associated with offspring lung function, whereas 25(OH)D levels during early childhood were not associated with later lung function, suggesting that the main long-term effects of vitamin D on lung function might be mediated via alterations in fetal lung development.

Vitamin D influences fetal lung growth and development, particularly during saccular and alveolar stages in late pregnancy.²³⁻²⁶ 25(OH)D is thought to readily cross the placenta in humans as it does in rats.²⁷ Furthermore, vitamin D receptors are expressed in lung and immune cells and *in vitro* studies have demonstrated that stimulation with 1,25-hydroxyvitamin D affects several key functions of fetal lung cells.^{24,28} However, it is unclear to what extent the effects of maternal 25(OH)D level on fetal lung development are attributed to the direct effects of vitamin D and whether there are other potential mediators such as differences in the plasma metabolites²⁹ of the mothers. Animal studies have demonstrated clear structural and functional lung changes in the offspring of vitamin D-deficient mothers.^{8,9} However, few studies have investigated the association between gestational 25(OH)D and offspring lung function in humans, and the results have been conflicting. While most studies have found no significant associations between gestational 25(OH)D level and child lung function,¹³⁻¹⁵ a weak positive association between maternal 25(OH)D level at 16-20 gestational weeks and child FVC at age 6 years was observed in the Australian Raine cohort.¹² We found that maternal 25(OH)D level at 10-18 gestational weeks and at third trimester were both significantly associated with offspring lung function. Interestingly, 25(OH)D level at 10-18 gestational weeks, during proximal airway branching, had the strongest associations with FVC

and FEV₁ which mainly reflect the function of larger airways, whereas 25(OH)D level at third trimester, during the development of the peripheral lung zone, showed the strongest associations with R5 and R5-20 which are more sensitive to changes in the peripheral airways.^{19,20} In contrast, child 25(OH)D level at age 1 or 3 years was not associated with later lung function.

Due to the lack of data on the optimal 25(OH)D level for respiratory health, we analyzed the effects of vitamin D on lung function by grouping subjects into quartiles based on the 25(OH)D level. A step-wise increase in child lung function was observed with increasing maternal 25(OH)D level quartiles. The difference in FEV₁, which is considered as the clinically most important lung function index, between the offspring of the lowest and highest maternal 25(OH)D level quartiles was over 10%. This exceeds the minimal clinically important difference (5-10%) based on adult studies³⁰ but because data on clinically significant differences in childhood lung function is lacking, further follow-up is needed to clarify the clinical significance of the observed lung function differences in later life and whether subjects who are exposed to low 25(OH)D levels *in utero* are at risk for altered longitudinal lung function trajectories.³¹ The highest baseline gestational 25(OH)D level quartile was ≥ 28.5 ng/ml and both the third and fourth quartiles of third trimester 25(OH)D level were ≥ 30 ng/ml, suggesting that a gestational 25(OH)D level of at least 30 ng/ml might be optimal for offspring respiratory health in contrast to 20 ng/ml which has traditionally been used to define vitamin D sufficiency based on studies on skeletal health.³² This was further supported by our secondary analyses, where the offspring of mothers with a 25(OH)D level of ≥ 30 ng/ml at baseline and at third trimester had significantly higher levels of lung function than those with lower maternal 25(OH)D levels, which is in line with results from the Raine cohort.¹²

Although the intention-to-treat analyses of the VDAART and COPSAC₂₀₁₀ trials resulted in weak or null associations between high-dose prenatal vitamin D₃ supplementation and childhood lung

304 function,^{16,17} we observed that maternal 25(OH)D levels at baseline and third trimester were
 305 significantly associated with offspring lung function. In addition to possible differences in
 306 adherence to the intervention and unaccounted vitamin D sources affecting the acquirement of
 307 vitamin D, genetic polymorphism may influence the increase in serum 25(OH)D level in response
 308 to supplementation.^{33,34} Therefore, plasma 25(OH)D level may provide a more precise measure of
 309 an individual's vitamin D status, explaining why the association with lung function was more
 310 evident with maternal 25(OH)D levels as opposed to the intention-to-treat analysis in VDAART.
 311 Furthermore, the vitamin D₃ supplementation may have been started too late (10-18 gestational
 312 weeks in VDAART and 22-26 gestational weeks in COPSAC₂₀₁₀) or at a suboptimal dose (4400
 313 IU/d in VDAART and 2800 IU/d in COPSAC₂₀₁₀) for most beneficial effects on offspring lung
 314 function, as we observed that maternal 25(OH)D level at 10-18 gestational weeks was significantly
 315 associated with offspring lung function and all subjects in the supplementation groups did not reach
 316 a 25(OH)D level of ≥ 30 ng/ml at third trimester.^{10,11} The associations between gestational 25(OH)D
 317 level and offspring lung function remained significant in the multivariable model which included
 318 other potential risk factors for lung function impairment such as childhood asthma phenotype,
 319 suggesting that gestational vitamin D has an independent effect on child lung function that is not
 320 mediated via changes in the risk of asthma. Furthermore, no significant interactions between
 321 gestational 25(OH)D level and child asthma were observed. Due to the notion of a “vitamin D
 322 paradox” with regard to African Americans, vitamin D, and osteoporosis,³⁵ we also conducted race-
 323 stratified analyses. We found similar effects of gestational 25(OH)D levels on offspring lung
 324 function between black and non-black participants in our cohort. Thus, higher 25(OH)D levels were
 325 associated with lower airway resistance and higher spirometry indices in both race categories.
 326 Organ system specific effects of vitamin D require further study.

327

328 Lung function deficits in asthma are often detectable by school age, when spirometry can be
 329 reliably performed, suggesting that impairment of lung function occurs earlier in life.^{2,36,37}
 330 However, few studies have evaluated the lung function trajectories of different asthma phenotypes
 331 during preschool years.³⁸ We observed that children with asthma at age 6 years in the VDAART
 332 cohort had significantly lower levels of lung function from 4 to 6 years of age than those in the
 333 asymptomatic/infrequent wheeze group, highlighting the importance of applicable lung function
 334 measurements for preschool age children to detect early lung function deficits. This is in line with
 335 previous studies that have reported an association between reduced infant lung function and asthma
 336 at school age³⁹ as well as persistent wheezing,¹ as the vast majority of the children with asthma at
 337 age 6 years in our study (91/105 [87%]) had asthmatic symptoms already during their first 3 years
 338 of life. Previous studies on the lung function of the early transient wheezing phenotype have been
 339 inconsistent.^{1,2,38,40} In our study, the early transient wheeze group showed subtle differences from
 340 the asymptomatic/infrequent wheeze group only in the IOS indices, particularly R5-20. Unlike
 341 spirometry, IOS requires only passive patient cooperation and can be reliably performed in
 342 preschool children.⁴¹ Our findings support a role for IOS in detecting early lung function deficits
 343 related to asthma, but validated multiethnic reference values are required for wider clinical
 344 implementation of IOS. Even though asthma control medications do not appear to affect the natural
 345 course of lung function in asthmatic subjects,⁴²⁻⁴⁴ they can have beneficial effects on asthma control
 346 and short-term lung function.^{45,46} Therefore, minimizing the effects of medications on lung function
 347 by selecting medication-naïve subjects with asthma or subjects with a longer medication cessation
 348 could be hypothesized to result in larger differences in the lung function of subjects with asthma
 349 when compared to asymptomatic controls than what was observed in the present study.
 350
 351 Environmental tobacco smoke exposure during pregnancy has been linked to different adverse birth
 352 outcomes such as stillbirth, low birth weight, and preterm birth,^{47,48} but its effects on offspring lung

function have not been fully elucidated. We found that even in the absence of active smoking of the mother, household tobacco smoking at study enrollment was associated with increased respiratory resistance in the children, suggesting that minimizing not only active smoking, but also secondhand smoke exposure during pregnancy could be important for offspring respiratory health. Further studies with objective measures of tobacco smoke exposure during pregnancy and early childhood could clarify the extent of exposure in subjects with detectable lung function deficits. In line with previous reports identifying preterm birth as an important risk factor for decreased lung function,^{49,50} we observed significant associations between preterm birth and lung function. Only 8 of the preterm children (16%) were born very preterm (<32 gestational weeks) when complications of prematurity are most often seen,⁵¹ highlighting that even moderate to late preterm birth might have significant effects on later lung function.⁵⁰

This study has several limitations. It should be acknowledged that loss to follow-up and missing data can lead to bias in longitudinal studies. However, comparison of child and parental baseline characteristics did not reveal any significant differences between the study subjects and those excluded except for a higher prevalence of maternal hay fever among the study subjects and differences in study site distribution. Furthermore, although our analyses were adjusted for different baseline characteristics of the mothers and children and the multivariable model included different risk factors for lung function impairment, the possibility of residual confounding should be acknowledged. Another limitation is that VDAART is a high-risk cohort for offspring asthma and half of the participating women received high-dose vitamin D₃ supplementation during pregnancy which might limit the generalizability of the results and therefore, further studies in unselected populations are required to confirm the optimal gestational 25(OH)D level for offspring respiratory health in the general population. Lastly, approximately half of the VDAART participants were black which is more than in the general US population.⁵² This is due to the baseline demographic

378 characteristics of the patient populations of the three study sites,⁵³ especially at St. Louis and
379 Boston (54% and 69% of the study subjects black, respectively) and the higher prevalence of atopic
380 diseases among black subjects than in the general US population,⁵⁴ as only women with a history of
381 atopic diseases in themselves or their partners were recruited for VDAART.

382

383 In conclusion, we found that low gestational 25(OH)D level and childhood asthma were
384 independently associated with decreased lung function from age 4 to 6 years. Both early and late
385 pregnancy 25(OH)D levels were significantly associated with offspring lung function and suggested
386 that gestational 25(OH)D level of ≥ 30 ng/ml might be optimal for offspring respiratory health in
387 subjects who are at high risk of asthma, but further studies are needed to define the optimal
388 gestational 25(OH)D level in the general population.

389 **ACKNOWLEDGEMENTS**

390 We wish to thank all the participants and study staff involved in the Vitamin D Antenatal Asthma
391 Reduction Trial.

392

393 **Funding:** National Heart Lung and Blood Institute R01HL091528 and UH3OD023268. HMK is
394 supported by Jane and Aatos Erkkö Foundation, Paulo Foundation, and the Pediatric Research
395 Foundation.

Journal Pre-proof

REFERENCES

1. Morgan WJ, Stern DA, Sherrill DL, Guerra S, Holberg CJ, Guilbert TW, et al. Outcome of asthma and wheezing in the first 6 years of life: follow-up through adolescence. *Am J Respir Crit Care Med* 2005;172:1253–8.
2. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, et al. A Longitudinal, Population-Based, Cohort Study of Childhood Asthma Followed to Adulthood. *N Engl J Med* 2003;349:1414–22.
3. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. *Lancet* 2007;370:758–64.
4. Turner S, Fielding S, Mullane D, W Cox Des, Goldblatt J, Lou Landau, et al. A longitudinal study of lung function from 1 month to 18 years of age. *Thorax* 2014;69:1015–20.
5. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? *J Steroid Biochem Mol Biol* 2014;144:138–45.
6. Johnson DD, Wagner CL, Hulsey TC, McNeil RB, Ebeling M, Hollis BW. Vitamin D deficiency and insufficiency is common during pregnancy. *Am J Perinatol* 2011;28:7–12.
7. Litonjua AA, Weiss ST. Is vitamin D deficiency to blame for the asthma epidemic? *J Allergy Clin Immunol* 2007;120:1031–5.
8. Mandell E, Ryan S, Seedorf GJ, Gonzalez T, Smith BJ, Fleet JC, et al. Maternal Vitamin D Deficiency Causes Sustained Impairment of Lung Structure and Function and Increases Susceptibility to Hyperoxia-Induced Lung Injury in Infant Rats. *Am J Respir Cell Mol Biol* 2020;63:79–91.
9. Zosky GR, Berry LJ, Elliot JG, James AL, Gorman S, Hart PH. Vitamin D deficiency causes deficits in lung function and alters lung structure. *Am J Respir Crit Care Med* 2011;183:1336–43.

- 421 10. Litonjua AA, Carey VJ, Laranjo N, Harshfield BJ, McElrath TF, O'Connor GT, et al. Effect
 422 of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in
 423 Offspring by Age 3 Years: The VDAART Randomized Clinical Trial. JAMA 2016;315:362–
 424 70.
- 425 11. Chawes BL, Bønnelykke K, Stokholm J, Vissing NH, Bjarnadóttir E, Schoos A-MM, et al.
 426 Effect of Vitamin D3 Supplementation During Pregnancy on Risk of Persistent Wheeze in
 427 the Offspring: A Randomized Clinical Trial. JAMA 2016;315:353–61.
- 428 12. Zosky GR, Hart PH, Whitehouse AJO, Kusel MM, Ang W, Foong RE, et al. Vitamin D
 429 deficiency at 16 to 20 weeks' gestation is associated with impaired lung function and asthma
 430 at 6 years of age. Ann Am Thorac Soc 2014;11:571–7.
- 431 13. Wills AK, Shaheen SO, Granell R, Henderson AJ, Fraser WD, Lawlor DA. Maternal 25-
 432 hydroxyvitamin D and its association with childhood atopic outcomes and lung function.
 433 Clin Exp Allergy 2013;43:1180–8.
- 434 14. Pike KC, Inskip HM, Robinson S, Lucas JS, Cooper C, Harvey NC, et al. Maternal late-
 435 pregnancy serum 25-hydroxyvitamin D in relation to childhood wheeze and atopic outcomes.
 436 Thorax 2012;67:950–6.
- 437 15. Cremers E, Thijs C, Penders J, Jansen E, Mommers M. Maternal and child's vitamin D
 438 supplement use and vitamin D level in relation to childhood lung function: the KOALA Birth
 439 Cohort Study. Thorax 2011;66:474–80.
- 440 16. Litonjua AA, Carey VJ, Laranjo N, Stubbs BJ, Mirzakhani H, O'Connor GT, et al. Six-Year
 441 Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. N Engl J Med
 442 2020;382:525–33.
- 443 17. Brustad N, Eliassen AU, Stokholm J, Bønnelykke K, Bisgaard H, Chawes BL. High-Dose
 444 Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6
 445 Years. JAMA 2019;321:1003–5.

- 446 18. Lu M, Hollis BW, Carey VJ, Laranjo N, Singh RJ, Weiss ST, et al. Determinants and
447 Measurement of Neonatal Vitamin D: Overestimation of 25(OH)D in Cord Blood Using
448 CLIA Assay Technology. *J Clin Endocrinol Metab* 2020;105:1085–92.
- 449 19. Foy BH, Soares M, Bordas R, Richardson M, Bell A, Singapuri A, et al. Lung
450 Computational Models and the Role of the Small Airways in Asthma. *Am J Respir Crit Care*
451 *Med* 2019;200:982–91.
- 452 20. Allen JL. Input oscillometry and the forced oscillation technique for assessing lung function
453 in preschool children with asthma. *Pediatric Investigation* 2018;2:37–43.
- 454 21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation
455 of spirometry. *Eur Respir J* 2005;26:319–38.
- 456 22. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic
457 reference values for spirometry for the 3-95-yr age range: the global lung function 2012
458 equations. *Eur Respir J* 2012;40:1324–43.
- 459 23. Damera G, Fogle HW, Lim P, Goncharova EA, Zhao H, Banerjee A, et al. Vitamin D
460 inhibits growth of human airway smooth muscle cells through growth factor-induced
461 phosphorylation of retinoblastoma protein and checkpoint kinase 1. *Br J Pharmacol*
462 2009;158:1429–41.
- 463 24. Nguyen M, Trubert CL, Rizk-Rabin M, Rehan VK, Besançon F, Cayre YE, et al. 1,25-
464 Dihydroxyvitamin D3 and fetal lung maturation: immunogold detection of VDR expression
465 in pneumocytes type II cells and effect on fructose 1,6 bisphosphatase. *J Steroid Biochem*
466 *Mol Biol* 2004;89-90:93–7.
- 467 25. Rehan VK, Torday JS, Peleg S, Gennaro L, Vouros P, Padbury J, et al. 1 α ,25-
468 dihydroxy-3-epi-vitamin D3, a natural metabolite of 1 α ,25-dihydroxy vitamin D3:
469 production and biological activity studies in pulmonary alveolar type II cells. *Mol Genet*
470 *Metab* 2002;76:46–56.

- 471 26. Nguyen TM, Guillozo H, Marin L, Tordet C, Koite S, Garabédian M. Evidence for a vitamin
472 D paracrine system regulating maturation of developing rat lung epithelium. *Am J Physiol*
473 1996;271:392–9.
- 474 27. Kovacs CS. Vitamin D in pregnancy and lactation: maternal, fetal, and neonatal outcomes
475 from human and animal studies. *Am J Clin Nutr*. 2008;88:520–8.
- 476 28. Litonjua AA. Childhood asthma may be a consequence of vitamin D deficiency. *Curr Opin*
477 *Allergy Clin Immunol* 2009;9:202–7.
- 478 29. Kelly RS, Chawes BL, Guo F, Zhang L, Blighe K, Litonjua AA, et al. The Role of the 17q21
479 Genotype in the Prevention of Early Childhood Asthma and Recurrent Wheeze by Vitamin
480 D. *Eur Respir J* 2019;54:1900761.
- 481 30. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for
482 COPD pharmacological trials: from lung function to biomarkers. *Eur Respir J* 2008;31:416–
483 69.
- 484 31. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, et al. Patterns of
485 Growth and Decline in Lung Function in Persistent Childhood Asthma. *N Engl J Med*
486 2016;374:1842–52.
- 487 32. Munns CF, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K, et al. Global Consensus
488 Recommendations on Prevention and Management of Nutritional Rickets. *J Clin Endocrinol*
489 *Metab* 2016;101:394–415.
- 490 33. Barry EL, Rees JR, Peacock JL, Mott LA, Amos CI, Bostick RM, et al. Genetic variants in
491 CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for
492 increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. *J Clin*
493 *Endocrinol Metab* 2014;99:2133–7.

- 494 34. Al-Daghri NM, Mohammed AK, Al-Attas OS, Ansari MGA, Wani K, Hussain SD, et al.
 495 Vitamin D Receptor Gene Polymorphisms Modify Cardiometabolic Response to Vitamin D
 496 Supplementation in T2DM Patients. *Sci Rep* 2017;7:8280–10.
- 497 35. Aloia JF. African Americans, 25-hydroxyvitamin D, and osteoporosis: a paradox. *Am J Clin*
 498 *Nutr* 2008;88:545S–550S.
- 499 36. Strunk RC, Sternberg AL, Szeffler SJ, Zeiger RS, Bender B, Tonascia J, et al. Long-term
 500 budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to
 501 moderate asthma in children and adolescents. *J Pediatr* 2009;154:682–7.
- 502 37. Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbison GP, et al. Risk
 503 factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital
 504 capacity ratio: a longitudinal population study from childhood to adulthood. *Am J Respir*
 505 *Crit Care Med* 2002;165:1480–8.
- 506 38. Lowe LAL, Simpson AA, Woodcock AA, Morris JJ, Murray CSC, Custovic AA. Wheeze
 507 phenotypes and lung function in preschool children. *Am J Respir Crit Care Med*
 508 2005;171:231–7.
- 509 39. Håland G, Carlsen KCL, Sandvik L, Devulapalli CS, Munthe-Kaas MC, Pettersen M, et al.
 510 Reduced lung function at birth and the risk of asthma at 10 years of age. *N Engl J Med*
 511 2006;355:1682–9.
- 512 40. Turner SW, Palmer LJ, Rye PJ, Gibson NA, Judge PK, Cox M, et al. The relationship
 513 between infant airway function, childhood airway responsiveness, and asthma. *Am J Respir*
 514 *Crit Care Med* 2004;169:921–7.
- 515 41. Beydon N, Davis SD, Lombardi E, Allen JL, Arets HGM, Aurora P, et al. An official
 516 American Thoracic Society/European Respiratory Society statement: pulmonary function
 517 testing in preschool children. *Am J Respir Crit Care Med* 2007;175:1304–45.

- 518 42. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A, IFWIN study team. Secondary
 519 prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants
 520 (IFWIN): double-blind, randomised, controlled study. *Lancet* 2006;368:754–62.
- 521 43. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled
 522 corticosteroids in infants with episodic wheezing. *N Engl J Med* 2006;354:1998–2005.
- 523 44. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szeffler SJ, et al. Long-term
 524 inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med*
 525 2006;354:1985–97.
- 526 45. Nieto A, et al. Montelukast improves pulmonary function measured by impulse oscillometry
 527 in children with asthma (Mio study). *Respir Med.* 2006 Jul;100(7):1180-5.
- 528 46. Pauwels RAR, Pedersen SS, Busse WWW, Tan WCW, Chen Y-ZY, Ohlsson SVS, et al.
 529 Early intervention with budesonide in mild persistent asthma: a randomised, double-blind
 530 trial. *Lancet* 2003;361:6–6.
- 531 47. Leonardi-Bee J, Britton J, Venn A. Secondhand smoke and adverse fetal outcomes in
 532 nonsmoking pregnant women: a meta-analysis. *PEDIATRICS* 2011;127:734–41.
- 533 48. Jaddoe VWV, Troe E-JWM, Hofman A, Mackenbach JP, Moll HA, Steegers EAP, et al.
 534 Active and passive maternal smoking during pregnancy and the risks of low birthweight and
 535 preterm birth: the Generation R Study. *Paediatr Perinat Epidemiol* 2008;22:162–71.
- 536 49. Simpson SJ, Turkovic L, Wilson AC, Verheggen M, Logie KM, Pillow JJ, et al. Lung
 537 function trajectories throughout childhood in survivors of very preterm birth: a longitudinal
 538 cohort study. *Lancet Child Adolesc Health* 2018;2:350–9.
- 539 50. Thunqvist P, Gustafsson PM, Schultz ES, Bellander T, Berggren-Broström E, Norman M, et
 540 al. Lung Function at 8 and 16 Years After Moderate-to-Late Preterm Birth: A Prospective
 541 Cohort Study. *PEDIATRICS* 2016;137:e20152056–6.

- 542 51. Kallapur SG, Ikegami M. Physiological consequences of intrauterine insults. *Paediatr Respir*
543 *Rev* 2006;7:110–6.
- 544 52. National Center for Health Statistics (US). *Health, United States, 2016: With Chartbook on*
545 *Long-term Trends in Health*. 2017.
- 546 53. Litonjua AA et al. The Vitamin D Antenatal Asthma Reduction Trial (VDAART): rationale,
547 design, and methods of a randomized, controlled trial of vitamin D supplementation in
548 pregnancy for the primary prevention of asthma and allergies in children. *Contemp Clin*
549 *Trials*. 2014;38:37–50.
- 550 54. Forno E, Celedón JC. Health disparities in asthma. *Am J Respir Crit Care Med*
551 2012;185:1033–5.

TABLES

Table 1. Baseline characteristics of subjects in the VDAART cohort (n=806) based on inclusion in the present study.

Characteristic	Study subjects (n=570)	Excluded (n=236)	P	Missing data (%)
Maternal age, mean (SD)	27.46 (5.51)	27.08 (5.49)	0.367	0
Maternal education, N (%)			0.335	0
< High school	76 (13.3)	24 (10.2)		
High school or technical school	164 (28.8)	77 (32.6)		
College or graduate school	330 (57.9)	135 (57.2)		
Household income, N (%)			0.687	0
< \$30,000	175 (30.7)	61 (25.8)		
\$30,000 - \$49,999	73 (12.8)	32 (13.6)		
\$50,000 - \$74,999	65 (11.4)	32 (13.6)		
> \$75,000	119 (20.9)	53 (22.5)		
Refused to say or unknown	138 (24.2)	58 (24.6)		
Environmental tobacco smoke exposure†, N (%)	93 (16.3)	29 (12.3)	0.179	0
Medical history of mother, N (%)				
Asthma	239 (41.9)	83 (35.2)	0.088	0
Hay fever	378 (66.3)	138 (58.5)	0.042	0
Eczema	178 (31.2)	79 (33.5)	0.589	0
Medical history of father, N (%)				
Asthma	140 (24.6)	47 (20.0)	0.193	0.2
Hay fever	243 (42.6)	101 (43.2)	0.952	0.2
Eczema	95 (16.7)	38 (16.3)	0.985	0.4
Vitamin D₃ intervention, N (%)	285 (50.0)	120 (50.8)	0.887	0
25-hydroxyvitamin D level (ng/ml, mean (SD))				
Mother at 10-18 gestational weeks	22.8 (10.2)	23.5 (10.4)	0.355	0.6
Mother at 32-38 gestational weeks	32.6 (14.4)	34.0 (15.2)	0.230	4.5
Cord blood at birth	23.6 (11.9)	23.5 (12.3)	0.904	23.6
Child at age 1 year	29.6 (9.7)	30.0 (10.8)	0.622	21.7
Child at age 3 years	21.6 (9.8)	20.2 (7.3)	0.201	30.5

Child sex (male, N (%))	295 (51.8)	126 (53.4)	0.730	0
Child race, N (%)			0.381	0
Black	284 (50.4)	106 (45.1)		
White	180 (31.9)	85 (36.2)		
Other	100 (17.7)	44 (18.7)		
Preterm birth[‡], N (%)	50 (8.8)	21 (9.0)	1.000	0.2
Child allergic sensitization[§], N (%)	340 (65.1)	46 (58.2)	0.286	25.4
Child asthma phenotype, N (%)			0.247	13.4
Asymptomatic / infrequent wheeze	377 (66.8)	80 (59.7)		
Early transient wheeze	82 (14.5)	26 (19.4)		
Asthma at age 6 years	105 (18.6)	28 (20.9)		
Study site (%)			0.004	0
Boston	157 (27.5)	83 (35.2)		
San Diego	186 (32.6)	88 (37.3)		
St. Louis	227 (39.8)	65 (27.5)		

[†]Exposure was defined as household tobacco smoking reported by the mother at study enrollment (10-18 gestational weeks). All women enrolled in the study were nonsmokers at study enrollment.

[‡]Gestational age <37 weeks.

[§]Serum specific IgE positive (≥ 35 kU/l) to ≥ 1 food or aeroallergen and/or total serum IgE level of ≥ 60 kU/l at the age of 3 and/or 6 years.

Table 2. Maternal 25-hydroxyvitamin D (25[OH]D) level quartiles at different time points and offspring lung function trajectories from 4 to 6 years of age.

	Impulse oscillometry					
	R5 (kPa/L/s)		R5-20 (kPa/L/s)			
	β [95% CI]	P	β [95% CI]	P		
Baseline†	-0.017	0.019	-0.011	0.041		
25(OH)D level quartiles	[-0.032 to -0.003]		[-0.021 to -0.001]			
Third trimester‡	-0.028	<0.001	-0.019	<0.001		
25(OH)D level quartiles	[-0.041 to -0.015]		[-0.029 to -0.010]			
Mean§	-0.021	0.003	-0.015	0.004		
25(OH)D level quartiles	[-0.035 to -0.007]		[-0.025 to -0.005]			
	Spirometry					
	FEV ₁ (L)		FVC (L)		FEV ₁ /FVC ratio	
	β [95% CI]	P	β [95% CI]	P	β [95% CI]	P
Baseline†	0.015	0.040	0.024	<0.001	-0.518	0.073
25(OH)D level quartiles	[0.001 to 0.028]		[0.010 to 0.038]		[-1.080 to 0.428]	
Third trimester‡	0.016	0.013	0.018	0.006	-0.038	0.884
25(OH)D level quartiles	[0.004 to 0.029]		[0.006 to 0.031]		[-0.550 to 0.473]	
Mean§	0.018	0.008	0.022	0.002	-0.122	0.660
25(OH)D level quartiles	[0.005 to 0.031]		[0.009 to 0.036]		[-0.664 to 0.419]	

†At 10-18 gestational weeks.

‡At 32-38 gestational weeks.

§Mean of maternal baseline and third trimester 25(OH)D levels.

Data presented as β estimates [95% confidence intervals] and p-values for the trend between the 25-hydroxyvitamin D level quartiles in the mixed effects models. Time-dependent covariates included in the model were child age (years) and height (cm). 25(OH)D level quartiles, sex, race, and study site were included as fixed covariates.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5, respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.

Table 3. Childhood asthma phenotypes and longitudinal lung function trajectories from 4 to 6 years of age.

	Impulse oscillometry					
	R5 (kPa/L/s)			R5-20 (kPa/L/s)		
	β [95% CI]	P		β [95% CI]	P	
Asthma phenotype						
Asymptomatic / infrequent wheeze		Ref.			Ref.	
Early transient wheeze	0.036 [-0.004 to 0.077]	0.081		0.035 [0.006 to 0.065]	0.021	
Asthma at age 6	0.065 [0.028 to 0.102]	<0.001		0.058 [0.031 to 0.085]	<0.001	
	Spirometry					
	FEV ₁ (L)		FVC (L)		FEV ₁ /FVC ratio	
	β [95% CI]	P	β [95% CI]	P	β [95% CI]	P
Asthma phenotype						
Asymptomatic / infrequent wheeze		Ref.		Ref.		Ref.
Early transient wheeze	0.012 [-0.024 to -0.049]	0.513	0.030 [-0.008 to 0.068]	0.123	-1.292 [-2.802 to 0.216]	0.097
Asthma at age 6	-0.063 [-0.099 to -0.028]	<0.001	-0.046 [-0.083 to -0.010]	0.015	-2.004 [-3.467 to -0.540]	0.008

Data presented as β estimates [95% confidence intervals] and p-values for the differences between the childhood asthma phenotypes when compared to asymptomatic children in the mixed effects models. Time-dependent covariates included in the model were child age (years) and height (cm). Childhood asthma phenotype, sex, race, and study site were included as fixed covariates. Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5, respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.

579 **Table 4.** Multivariable mixed effects model for the longitudinal lung function trajectories.

	Impulse oscillometry					
	R5 (kPa/L/s)		R5-20 (kPa/L/s)			
	β [95% CI]	P	β [95% CI]	P		
Mean† gestational 25(OH)D level quartile	-0.019 [-0.032 to -0.005]	0.008	-0.012 [-0.022 to -0.002]	0.020		
Asthma phenotype						
Asymptomatic / infrequent wheeze	Ref.		Ref.			
Early transient wheeze	0.025 [-0.016 to 0.066]	0.232	0.027 [-0.003 to 0.057]	0.077		
Asthma at age 6	0.055 [0.018 to 0.093]	0.005	0.051 [0.024 to 0.079]	<0.001		
Preterm birth‡	0.049 [-0.008 to 0.106]	0.095	0.052 [0.011 to 0.094]	0.015		
ETS exposure§	0.064 [0.023 to 0.104]	0.003	0.044 [0.014 to 0.074]	0.004		
	Spirometry					
	FEV ₁ (L)		FVC (L)		FEV ₁ /FVC ratio	
	β [95% CI]	P	β [95% CI]	P	β [95% CI]	P
Mean† gestational 25(OH)D level quartile	0.016 [0.003 to 0.029]	0.015	0.022 [0.008 to 0.035]	0.002	-0.202 [-0.743 to 0.337]	0.468
Asthma phenotype						
Asymptomatic / infrequent wheeze	Ref.		Ref.		Ref.	
Early transient wheeze	0.025 [-0.013 to 0.062]	0.209	0.045 [0.006 to 0.084]	0.026	-1.368 [-2.934 to 0.194]	0.091
Asthma at age 6	-0.053 [-0.089 to -0.017]	0.005	-0.037 [-0.075 to 0.000]	0.056	-1.800 [-3.304 to -0.293]	0.021
Preterm birth‡	-0.063 [-0.116 to -0.009]	0.024	-0.053 [-0.109 to 0.002]	0.063	-1.198 [-3.436 to 1.041]	0.301
ETS exposure§	-0.017 [-0.055 to 0.020]	0.372	-0.026 [-0.065 to 0.013]	0.195	0.096 [-1.476 to 1.665]	0.906

580 [†]Mean of maternal baseline (10-18 gestational weeks) and third trimester (32-38 gestational weeks)
 581 25-hydroxyvitamin D levels.

582 [‡]Gestational age <37 weeks.

583 [§]Environmental tobacco smoke (ETS) exposure defined as tobacco smoking in the household
 584 reported by the mother at the time of study enrollment (10-18 gestational weeks). All mothers
 585 enrolled in the study were nonsmokers at enrollment.

586 Data presented as β estimates [95% confidence intervals] and p-values for all risk factors in the
 587 mixed effects models. Time-dependent covariates included in the model were child age (years) and
 588 height (cm). 25(OH)D level quartiles, childhood asthma phenotype, preterm birth, ETS exposure,
 589 sex, race, and study site were included as fixed covariates.

590 Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5,
591 respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.



FIGURE LEGENDS


Figure 1. Flow chart of the study. Abbreviations: 25(OH)D, 25-hydroxyvitamin D; IOS, impulse oscillometry; VDAART, Vitamin D Antenatal Asthma Reduction Trial.


Figure 2. Mean values for child lung function at ages 4, 5, and 6 years stratified by maternal 25-hydroxyvitamin D level quartiles during pregnancy (mean value of the levels at 10-18 gestational weeks and at 32-38 gestational weeks). A) respiratory resistance at 5 Hz (R5), and B) forced expiratory volume in 1 second (FEV1)²². Data points illustrate the mean values of the lung function indices for each group and the whiskers illustrate the 95% confidence interval.


Figure 3. Mean values for child lung function at ages 4, 5, and 6 years among the subset of children whose mothers had either deficient (<20 ng/ml, n=91), insufficient (20-29 ng/ml, n=61), or sufficient ($\geq$ 30 ng/ml, n=96) 25-hydroxyvitamin D level at both baseline (10-18 gestational weeks) and third trimester (32-38 gestational weeks). A) respiratory resistance at 5 Hz (R5), and B) forced expiratory volume in 1 second (FEV1)²². Data points illustrate the mean values of the lung function indices for each group and the whiskers illustrate the 95% confidence interval.


Figure 4. Mean values for child lung function at ages 4, 5, and 6 years stratified by childhood asthma phenotype. A) respiratory resistance at 5 Hz (R5), and B) forced expiratory volume in 1 second (FEV1)²². Data points illustrate the mean values of the lung function indices for each group and the whiskers illustrate the 95% confidence interval.











ONLINE REPOSITORY**Low gestational vitamin D level and childhood asthma are related to impaired lung function in high-risk children**

Authors: Hanna M. Knihtilä, MD, PhD; Benjamin J. Stubbs, BA; Vincent J. Carey, PhD; Nancy Laranjo, BA; Su H. Chu, PhD; Rachel S. Kelly, PhD; Robert S. Zeiger, MD, PhD; Leonard B. Bacharier, MD; George T. O'Connor, MD, MS; Jessica Lasky-Su, ScD; Scott T. Weiss, MD, MS^{*}; Augusto A. Litonjua, MD, MPH^{*}

Affiliations: ¹Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States

²Departments of Allergy and Research and Evaluation, Kaiser Permanente Southern California Region, San Diego, CA and Pasadena, CA

³The Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis

⁴The Pulmonary Center, Department of Medicine, Boston University School of Medicine

⁵Division of Pediatric Pulmonary Medicine, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, NY, United States

^{*}These authors contributed equally

Corresponding author: Scott T. Weiss, MD, MS. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA 02115. Telephone: 617-525-2278. Fax: 617-525-0958. Email: scott.weiss@channing.harvard.edu.

24 TABLES

25 **Table E1.** Maternal 25-hydroxyvitamin D (25[OH]D) level quartiles at different time points and
 26 offspring lung function trajectories from 4 to 6 years of age.

	Impulse oscillometry					
	R5 (kPa/L/s)			R5-20 (kPa/L/s)		
	β		P	β		P
Baseline†						
25(OH)D level quartiles	-0.016		0.033	-0.010		0.073
Third trimester‡						
25(OH)D level quartiles	-0.028		<0.001	-0.019		<0.001
Mean§						
25(OH)D level quartiles	-0.021		0.002	-0.015		0.004
	Spirometry					
	FEV ₁ (L)		FVC (L)		FEV ₁ /FVC ratio	
	β		P	β		P
Baseline†						
25(OH)D level quartiles	0.015		0.038	0.024		0.001
Third trimester‡						
25(OH)D level quartiles	0.016		0.012	0.018		0.006
Mean§						
25(OH)D level quartiles	0.019		0.007	0.022		0.002

27 †At 10-18 gestational weeks.

28 ‡At 32-38 gestational weeks.

29 §Mean of maternal baseline and third trimester 25(OH)D levels.

30 Data presented as β estimates [95% confidence intervals] and p-values for the trend between the 25-
 31 hydroxyvitamin D level quartiles in the mixed effects models. Time-dependent covariates included
 32 in the model were child age (years) and height (cm). 25(OH)D level quartiles, sex, race, study site,
 33 maternal age, maternal education level, maternal asthma, and household tobacco smoking at
 34 enrollment were included as fixed covariates.

35 Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5,
 36 respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.

Table E2. Maternal 25-hydroxyvitamin D (25[OH]D) level quartiles at different time points and offspring lung function trajectories from 4 to 6 years of age among subjects with data on allergic sensitization (n=522).

	Impulse oscillometry					
	R5 (kPa/L/s)			R5-20 (kPa/L/s)		
	β		P	β		P
Baseline† 25(OH)D level quartiles	-0.016		0.032	-0.010		0.080
Third trimester‡ 25(OH)D level quartiles	-0.028		<0.001	-0.019		<0.001
Mean§ 25(OH)D level quartiles	-0.020		0.006	-0.015		0.008
	Spirometry					
	FEV ₁ (L)		FVC (L)		FEV ₁ /FVC ratio	
	β		P	β		P
Baseline† 25(OH)D level quartiles	0.013		0.083	0.023		0.003
Third trimester‡ 25(OH)D level quartiles	0.015		0.028	0.017		0.016
Mean§ 25(OH)D level quartiles	0.016		0.028	0.020		0.008

†At 10-18 gestational weeks.

‡At 32-38 gestational weeks.

§Mean of maternal baseline and third trimester 25(OH)D levels.

Data presented as β estimates [95% confidence intervals] and p-values for the trend between the 25-hydroxyvitamin D level quartiles in the mixed effects models. Time-dependent covariates included in the model were child age (years) and height (cm). 25(OH)D level quartiles, sex, race, study site, and allergic sensitization were included as fixed covariates.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5, respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.

Table E3. Sex-stratified mixed effects models for the longitudinal lung function trajectories of children categorized by maternal 25-hydroxyvitamin D (25[OH]D) level quartiles at different time points.

Males (n=295)								
	Impulse oscillometry				Spirometry			
	R5 (kPa/L/s)		R5-20 (kPa/L/s)		FEV ₁ (L)		FVC (L)	
	β	P	β	P	β	P	β	P
Baseline†								
25(OH)D level quartiles	-0.011	0.302	-0.003	0.749	0.014	0.192	0.027	0.013
Third trimester‡ 25(OH)D level quartiles	-0.027	0.005	-0.016	0.035	0.020	0.051	0.022	0.032
Mean§								
25(OH)D level quartiles	-0.019	0.064	-0.009	0.262	0.019	0.066	0.025	0.018
Females (n=275)								
	Impulse oscillometry				Spirometry			
	R5 (kPa/L/s)		R5-20 (kPa/L/s)		FEV ₁ (L)		FVC (L)	
	β	P	β	P	β	P	β	P
Baseline†								
25(OH)D level quartiles	-0.023	0.026	-0.018	0.011	0.017	0.058	0.023	0.014
Third trimester‡ 25(OH)D level quartiles	-0.026	0.005	-0.021	0.001	0.013	0.114	0.018	0.046
Mean§								
25(OH)D level quartiles	-0.020	0.042	-0.020	0.004	0.018	0.040	0.022	0.018

†At 10-18 gestational weeks.

‡At 32-38 gestational weeks.

§Mean of maternal baseline and third trimester 25-hydroxyvitamin D levels.

Data presented as β estimates and p-values for the trend between the 25-hydroxyvitamin D level quartiles in mixed effects models. Time-dependent covariates included in the model were child age (years) and height (cm). 25(OH)D level quartiles, race, and study site were included as fixed covariates.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5, respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.

Table E4. Race-stratified mixed effects models for the longitudinal lung function trajectories of children categorized by maternal 25-hydroxyvitamin D (25[OH]D) level at different time points.

Blacks (n=284)								
	Impulse oscillometry				Spirometry			
	R5 (kPa/L/s)		R5-20 (kPa/L/s)		FEV₁ (L)		FVC (L)	
	β	P	β	P	β	P	β	P
Baseline[†]								
25(OH)D level quartiles	-0.015	0.150	-0.005	0.508	0.019	0.053	0.025	0.012
Third trimester[‡] 25(OH)D level quartiles	-0.021	0.021	-0.016	0.018	0.018	0.031	0.015	0.091
Mean[§]								
25(OH)D level quartiles	-0.016	0.113	-0.011	0.119	0.018	0.046	0.015	0.104
Other races (n=286)								
	Impulse oscillometry				Spirometry			
	R5 (kPa/L/s)		R5-20 (kPa/L/s)		FEV₁ (L)		FVC (L)	
	β	P	β	P	β	P	β	P
Baseline[†]								
25(OH)D level quartiles	-0.020	0.065	-0.015	0.061	0.011	0.315	0.020	0.077
Third trimester[‡] 25(OH)D level quartiles	-0.035	<0.001	-0.022	0.003	0.012	0.216	0.020	0.047
Mean[§]								
25(OH)D level quartiles	-0.026	0.011	-0.017	0.027	0.016	0.119	0.025	0.017

[†]At 10-18 gestational weeks.

[‡]At 32-38 gestational weeks.

[§]Mean of maternal baseline and third trimester 25-hydroxyvitamin D levels.

Data presented as β estimates and p-values for the trend between the 25-hydroxyvitamin D level quartiles in the mixed effects models. Time-dependent covariates included in the model were child age (years) and height (cm). 25(OH)D level quartiles, sex, and study site were included as fixed covariates.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5, respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.

Table E5. 25-hydroxyvitamin D (25[OH]D) level quartiles during early life and longitudinal lung function trajectories from 4 to 6 years of age.

	Impulse oscillometry							
	R5 (kPa/L/s)				R5-20 (kPa/L/s)			
	β		P		β		P	
	β	P	β	P	β	P		
Cord blood 25(OH)D level quartiles	-0.015	0.045	-0.012	0.024				
Age 1 25(OH)D level quartiles	-8.8*10 ⁻⁵	0.990	0.001	0.785				
Age 3 25(OH)D level quartiles	-0.009	0.206	-0.007	0.215				
	Spirometry							
	FEV ₁ (L)		FVC (L)		FEV ₁ /FVC ratio			
	β		P		β		P	
	β	P	β	P	β	P		
Cord blood 25(OH)D level quartiles	0.007	0.298	0.011	0.127	-0.284	0.333		
Age 1 25(OH)D level quartiles	0.002	0.809	0.002	0.776	-0.009	0.973		
Age 3 25(OH)D level quartiles	0.005	0.529	0.007	0.347	-0.063	0.834		

Data presented as β estimates and p-values for the trend between the 25-hydroxyvitamin D level quartiles in the mixed effects models. Time-dependent covariates included in the model were child age (years) and height (cm). 25(OH)D level quartiles, sex, race, and study site were included as fixed covariates.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5, respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.

Table E6. Gestational 25-hydroxyvitamin D (25[OH]D) level groups and offspring longitudinal lung function trajectories from 4 to 6 years of age.

	Impulse oscillometry					
	R5 (kPa/L/s)		R5-20 (kPa/L/s)			
	β	P	β	P		
Gestational 25(OH)D level						
<20ng/ml	0.094	0.003	0.063	0.006		
20-29 ng/ml	0.078	0.007	0.042	0.046		
≥30 ng/ml	Ref.		Ref.			
Trend	0.049	0.002	0.032	0.005		
	Spirometry					
	FEV ₁ (L)		FVC (L)		FEV ₁ /FVC ratio	
	β	P	β	P	β	P
Gestational 25(OH)D level						
<20ng/ml	-0.081	0.007	-0.098	0.001	0.378	0.761
20-29 ng/ml	-0.041	0.138	-0.035	0.215	-0.851	0.465
≥30 ng/ml	Ref.		Ref.		Ref.	
Trend	-0.041	0.007	-0.048	0.001	0.123	0.842

Only subjects who fulfilled the 25-hydroxyvitamin D level criteria both at baseline (10-18 gestational weeks) and at third trimester (32-38 gestational weeks) were included in the analysis. Numbers of subjects in each subgroup: n=91 for <20 ng/ml, n=61 for 20-29 ng/ml, and n=96 for ≥ 30 ng/ml. Data presented as β estimates and p-values for each group and for the trend between the groups in the mixed effect models. Time-dependent covariates included in the model were child age (years) and height (cm). 25(OH)D level group, sex, race, and study site were included as fixed covariates. Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5, respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.

Table E7. Childhood asthma phenotypes and longitudinal lung function trajectories from 4 to 6 years of age among subjects with data on allergic sensitization (n=522).

	Impulse oscillometry					
	R5 (kPa/L/s)			R5-20 (kPa/L/s)		
	β	P		β	P	
Asthma phenotype						
Asymptomatic / infrequent wheeze		Ref.			Ref.	
Early transient wheeze	0.044	0.038		0.039	0.013	
Asthma at age 6	0.063	0.002		0.056	<0.001	
	Spirometry					
	FEV ₁ (L)		FVC (L)		FEV ₁ /FVC ratio	
	β	P	β	P	β	P
Asthma phenotype						
Asymptomatic / infrequent wheeze		Ref.		Ref.		Ref.
Early transient wheeze	0.011	0.574	0.026	0.194	-1.119	0.161
Asthma at age 6	-0.059	0.002	-0.046	0.021	-1.604	0.044

Data presented as β estimates [95% confidence intervals] and p-values for the trend between the 25-hydroxyvitamin D level quartiles in the mixed effects models. Time-dependent covariates included in the model were child age (years) and height (cm). Childhood asthma phenotype, sex, race, study site, and allergic sensitization were included as fixed covariates.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5, respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.

Table E8. Interaction between maternal 25-hydroxyvitamin D (25[OH]D) level quartiles and child asthma status at age 6 years for the longitudinal lung function trajectories.

	Impulse oscillometry			
	R5 (kPa/L/s)		R5-20 (kPa/L/s)	
	β	P	β	P
Baseline† 25(OH)D quartiles * asthma	0.002	0.924	0.008	0.536
Third trimester‡ 25(OH)D quartiles * asthma	0.014	0.423	0.007	0.574
Mean§ 25(OH)D quartiles * asthma	0.011	0.528	0.009	0.491
	Spirometry			
	FEV₁ (L)		FVC (L)	
	β	P	β	P
Baseline† 25(OH)D quartiles * asthma	-0.010	0.538	0.003	0.842
Third trimester‡ 25(OH)D quartiles * asthma	-0.014	0.388	0.020	0.248
Mean§ 25(OH)D quartiles * asthma	2.6*10 ⁻⁵	0.999	-0.004	0.799

†At 10-18 gestational weeks.

‡At 32-38 gestational weeks.

§Mean of maternal baseline and third trimester 25-hydroxyvitamin D levels.

Data presented as β estimates and p-values for the interaction between 25-hydroxyvitamin D level quartiles and child asthma status at age 6 years (yes/no) in the mixed effects models. Time-dependent covariates included in the model were child age (years) and height (cm). 25(OH)D level quartiles, child asthma status at age 6 years, sex, race, and study site were included as fixed covariates.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; R5, respiratory resistance at 5 Hz; R5-20, difference between respiratory resistance at 5 and 20 Hz.

111 **FIGURE LEGENDS**

112 **Figure E1.** Upset diagrams illustrating the number of subjects who performed successful A)
113 impulse oscillometry (IOS) and B) spirometry measurements at each visit.